Prana: New Cognition Test Works In Alzheimer’s Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Gold standard ADAS-cog might be on its way out.
You may also be interested in...
The Alzheimer's Divide
Issues of clinical trial design are at the forefront in Alzheimer's drug development. Researchers and investors are weighing the impact of late-stage failures, even as significant unknowns remain about disease mechanism and the correlation of biochemical markers and clinical effects. A fundamental question hangs over AD drug development, which is unique in many respects: in deciding how to move from Phase II into Phase III, what can you know and how can you know it?
NTB Measure Gains Ground In Alzheimer's
Investigator in Elan, Lilly and Myriad trials tells “The Pink Sheet” DAILY he is generally optimistic.
NTB Measure Gains Ground In Alzheimer's
Investigator in Elan, Lilly and Myriad trials tells “The Pink Sheet” DAILY he is generally optimistic.